Business
Sema4 Announces Chief Financial Officer Transition Plan
Appoints Richard Miao, Sema4’s Deputy Chief Financial Officer, as interim Chief Financial Officer Reiterates the financial guidance provided on May 12, 2022
About this update from Genedx Holdings Corp.
[{"type":"text","content":"Appoints Richard Miao, Sema4’s Deputy Chief Financial Officer, as interim Chief Financial Officer Reiterates the financial guidance provided on May 12, 2022 STAMFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced its Chief Financial Officer (CFO), Isaac Ro, will be leaving the company on August 9, 2022. Effective immediately, Richard Miao, Sema4’s Deputy CFO, will serve as interim CFO while the company conducts a search for a permanent CFO. Mr. Ro will provide consulting services to Sema4 for six months to facilitate a smooth transition of responsibilities. “We are extremely thankful for Isaac’s leadership and experience as he helped guide Sema4’s evolution into a publicly traded company, build a strong finance team, and close the acquisition of GeneDx,\" said Katherine Stueland, Chief Executive Officer of Sema4. “We offer Isaac our deepest gratitude and we wish him continued success in his next endeavor.” Ms. Stueland continued: “As we look to our next phase of commercial growth and continuing on the path to profitability, we remain committed to further accelerating precision medicine as the standard of care. We look forward to welcoming a new CFO who will help us further drive our goals and mission.” “Sema4 has grown rapidly over the past eighteen months and has evolved into an industry-leading health intelligence company,” said Mr. Ro. “Looking forward, there are significant growth opportunities across many disease areas as well as a path to profitability for Sema4. I am honored to have helped lead the company’s transformation and am excited about the prospects of the business.” Mr. Miao has more than 18 years of experience in Corporate Finance across multiple growth industries and will report directly to Ms. Stueland in his interim role. Mr. Ro’s departure is not related to any disagreement with the company’s accounting principles or practices or financial statement disclosures. The company has engaged Russell Reynolds to conduct the search for Mr. Ro’s permanent replacement. About Sema4Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genom...